Evidence map›Paper›PMID 38948021›Full record

ArticleOncology research2024

ROR2 promotes invasion and chemoresistance of triple-negative breast cancer cells by activating PI3K/AKT/mTOR signaling.

Xia DA, Han Ge, Junfeng Shi, Chunhua Zhu, Guozhu Wang, Yuan Fang, Jin Xu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xia DADepartment of Breast and Thyroid, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Han GeDepartment of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Junfeng ShiDepartment of Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Chunhua ZhuDepartment of Breast and Thyroid, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Guozhu WangDepartment of Breast and Thyroid, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Yuan FangDepartment of Pathology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Jin XuDepartment of Breast and Thyroid, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: This study aimed to investigate the role of receptor tyrosine kinase-like orphan receptor 2 (ROR2) in triple-negative breast cancer (TNBC). Methods: ROR2 expression in primary TNBC and metastatic TNBC tissues was analyzed by immunohistochemical staining and PCR. ROR2 expression in TNBC cell lines was detected by PCR and Western blot analysis. The migration, invasion and chemosensitivity of TNBC cells with overexpression or knockdown of ROR2 were examined. Results: ROR2 expression was high in metastatic TNBC tissues. ROR2 knockdown suppressed the migration, invasion and chemoresistance of TNBC cells. ROR2 overexpression in MDA-MB-435 cells promoted the migration, invasion, and chemoresistance. Moreover, ROR2 knockdown in HC1599 and MDA-MB-435 adriamycin-resistant cells enhanced chemosensitivity to adriamycin. ROR2 could activate PI3K/AKT/mTOR signaling in TNBC cells. Conclusion: ROR2 is upregulated and promotes metastatic phenotypes of TNBC by activating PI3K/AKT/mTOR signaling.

Indexed as

Cell MovementDrug Resistance, NeoplasmNeoplasm InvasivenessPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktReceptor Tyrosine Kinase-like Orphan ReceptorsSignal TransductionTOR Serine-Threonine KinasesTriple Negative Breast NeoplasmsCell Line, TumorDoxorubicinFemaleGene Expression Regulation, NeoplasticHumansDoxorubicinMTOR protein, humanPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktReceptor Tyrosine Kinase-like Orphan ReceptorsROR2 protein, humanTOR Serine-Threonine KinasesApoptosisMetastasisPI3K/AKT/mTOR signalingProliferationReceptor tyrosine kinase-like orphan receptor 2Triplet-negative breast cancer

Identifiers

PMID38948021
PMCPMC11209745

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.